The Primary
Care Companionfor CNS Disorders

Schizophrenia/Schizoaffective Disorders

Original Research June 15, 2005

CME Article: The Relation Between Body Fat Distribution and Cardiovascular Risk Factors in Patients With Schizophrenia: A Cross-Sectional Pilot Study

Martha M. Lato ; M. Beatriz Currier ; Oscar Villaverde ; Mercedes Gonzalez-Blanco

Prim Care Companion J Clin Psychiatry 2005;7(3):115-118

Article Abstract

Schizophrenia Weight Cardiovascular Health

Download Free PDF

This PDF is free for all visitors!

Save

Cite

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Vol 27 • 2025 • Number 1

Read the Current Issue

Rounds in the General Hospital

Psychosis-Related PTSD

Case Report

Thyrotoxic Psychosis in Graves’ Disease

Case Report

Factitious Disorder in the Context of Abuse in an Adolescent

Rounds in the General Hospital

Wishing That Your Patient Would Die: Reasons and Reactions

Case Report

Frontal Lobe Syndrome Unveils an Unexpected Diagnosis

Case Report

Low-Dose Clozapine in Schizophrenia With Aggression

View current Issue

Original Research

Olanzapine/Samidorphan Effects on Weight Gain

January 2, 2025

Treatment with a combination of olanzapine and samidorphan was associated with less weight gain and reduced risk of reaching ≥7% or ≥10% gain in body weight versus olanzapine over...

Christoph U. Correll , Michael J. Doane , David McDonnell , et al

Original Research

Long-Term Safety and Treatment Effect of Olanzapine/Samidorphan

December 4, 2024

During up to 4 years of treatment, the combination of olanzapine/samidorphan was safe and well-tolerated, and patients’ symptoms remained stable.

Jacob S. Ballon , René S. Kahn , Christina Arevalo , et al

Original Research

Aripiprazole Lauroxil Initiation Regimens

August 12, 2024

In separate studies of the two initiation methods, the numbers of people who had side effects were similar, and most side effects were mild.

Roger W. Sommi , Stephen R. Saklad , Peter J. Weiden , et al

CME Article: The Relation Between Body Fat Distribution and Cardiovascular Risk Factors in Patients With Schizophrenia: A Cross-Sectional Pilot Study

Read the Current Issue

Psychosis-Related PTSD

Thyrotoxic Psychosis in Graves’ Disease

Factitious Disorder in the Context of Abuse in an Adolescent

Wishing That Your Patient Would Die: Reasons and Reactions

Frontal Lobe Syndrome Unveils an Unexpected Diagnosis

Low-Dose Clozapine in Schizophrenia With Aggression

ELSEWHERE:

FOLLOW US:

CME Article: The Relation Between Body Fat Distribution and Cardiovascular Risk Factors in Patients With Schizophrenia: A Cross-Sectional Pilot Study

Read the Current Issue

Psychosis-Related PTSD

Thyrotoxic Psychosis in Graves’ Disease

Factitious Disorder in the Context of Abuse in an Adolescent

Wishing That Your Patient Would Die: Reasons and Reactions

Frontal Lobe Syndrome Unveils an Unexpected Diagnosis

Low-Dose Clozapine in Schizophrenia With Aggression

Related Articles

Olanzapine/Samidorphan Effects on Weight Gain

Long-Term Safety and Treatment Effect of Olanzapine/Samidorphan

Aripiprazole Lauroxil Initiation Regimens

Watch the New PsychCase360

Subscribe to readmore articles

Subscribe to read
more articles